Table 1.
Variables |
E. coli 115 Episodes N (%) |
K. pneumoniae 69 Episodes N (%) |
---|---|---|
Age (years; median [IQR]) | 58 (50–67) | 61 (50–69) |
Female patients | 71 (61.7) | 42 (60.9) |
Charlson Comorbidity Index (median [IQR]) | 3 (3–5) | 5 (3–5) |
Months from transplantation (median [IQR]) | 14 (4–77) | 6 (1–77) |
<2 months from transplantation | 21 (18.3) | 41 (59.4) |
Previous kidney transplantation | 10 (8.7) | 8 (11.6) |
Living donor | 11 (9.5) | 6 (8.7) |
Induction therapy within 3 previous months:
|
73 (63.5) 26 (22.6) 41 (35.7) 6 (5.2) |
28 (40.6) 12 (17.4) 14 (20.3) 2 (2.9) |
Current immunosuppression:
|
107 (93.0) 107 (93.0) 90 (78.3) 8 (6.9) 4 (3.4) |
58 (84.1) 64 (92.8) 54 (78.3) 4 (5.8) 3 (4.3) |
Acute rejection within the previous 6 months | 11 (9.6) | 0 (0.0) |
Rejection treatment in the previous 6 months:
|
9 (7.9) 1 (0.9) 1 (0.9) |
- - - |
Creatinine (mg/dL; median [IQR]) | 1.57 (1.21–1.95) | 1.56 (1.25–1.99) |
Bacteriuria within the previous 6 months | 57 (49.6) | 49 (71.0) |
Antibiotic use within the previous 3 months
|
48 (41.7) 11 (9.6) 6 (5.2) 14 (12.2) 15 (13.0) 2 (1.7) |
30 (43.5) 3 (4.3) 8 (11.6) 10 (14.5) 7 (10.1) 2 (2.9) |
Cystitis | 19 (16.5) | 33 (47.8) |
Asymptomatic bacteriuria | 96 (83.5) | 36 (52.2) |
Urinary pH (median [IQR]) | 6 (6–6.5) | 6.5 (6–6.5) |
Baseline antibiotic resistance:
|
66 (57.4) 30 (26.1) 24 (20.9) 10 (8.7) 2 (1.7) 2 (1.7) |
42 (60.9) 20 (29.0) 15 (21.7) 8 (11.6) 21 (30.4) 20 (29.0) |
Antibiotic therapy of the UTI episodes
|
88 (76.5) 27 (23.5) |
46 (66.7) 23 (33.3) |
IQR: Interquartile range; MMF: Mycophenolate mofetil; mTOR inhibitors: Sirolimus, everolimus; ESBL: Extended spectrum beta-lactamases; * Quinolones: ciprofloxacin or levofloxacin; ** Cephalosporins: cefixime or cefuroxime; *** Others: Ertapenem, cloxacillin and rifaximine; **** Cephalosporins: cefuroxime, cefotaxime, ceftazidime, cefixime or cefepime.